+38.3%
LIN vs MRNA
+275.0%
-236.7%
-19.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +5.8% | -4.8% | +0.9% |
| 7D | +0.1% | +21.8% | -21.7% | -0.1% |
| 30D | +7.6% | +19.6% | -12.0% | +7.3% |
| 3M | +6.5% | +354.6% | -348.1% | +3.7% |
| 6M | +6.2% | +394.9% | -388.7% | +2.8% |
| YTD | +23.2% | +812.2% | -788.9% | +16.3% |
| 1Y | +25.4% | +996.2% | -970.8% | +17.4% |
| 3Y | +38.3% | +287.0% | -248.7% | +31.9% |
| All | +38.3% | +275.0% | -236.7% | +31.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling